COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Read our FAQs.

New investigational drug for patients with previously treated CLL/SLL or NHL

Trial ID:
IRB-21-7749
Marin Xavier, MD
The purpose of this study is to assess the preliminary anti-tumor activity of the investigational oral drug LOXO-305 as single therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)and B-cell non-Hodgkin lymphoma (NHL) who have failed or are intolerant to standard of care.

This study requires weekly visits for the first month, then monthly visits from the second month on.

Inclusion Criteria

Patients must:
  • Patients must:
  • Be at least 18 years of age
  • Have an ECOG score of 0-2
  • Have a tumor sample available that was obtained after most recent treatment or be willing to get one

Exclusion Criteria

Patients must not:
  • Patients must not:
  • Be on prior anticancer therapy within 4 weeks before the first dose of the investigational drug
  • Have had major surgery within 4 weeks prior to planned start
  • Be on warfarin
  • Have tested positive for Human Immunodeficiency Virus (HIV)

Additional Info

  • For more information about this clinical trial, search for NCT03740529 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org